The facility focuses on the manufacture of novel monoclonal antibody hybridoma clones for research and clinical use at Flinders University and Medical Centre. Services provided include immunization of animal species, generation of hybridomas, isolation of clonal cell lines and testing for high titre/high affinity clones.
The clones and their antibody products have additional potential use as commercial research reagents, novel diagnostics and therapeutics. Excess clones/reagents are on-sold and distributed worldwide via reagent companies, bringing in funding for University/Medical School research and the production of new reagents.
Funding for new reagents is available to Flinders Researchers through Flinders PartnersSinead O'Connell PhD
Senior Associate – Technology Development
Internal Organisations, Flinders Partners Pty Ltd
Phone (+61 8) 8201 7716